Trending...
- New Rochelle Police Arrest Suspect in Child Grooming Sting Operation
- New Rochelle Police Arrest Two Following Assault at Gas Station
- Corcoran DeRonja Real Estate Welcomes Mechelle Fuquay as Its Newest Broker
WILMINGTON, Del., Feb. 6, 2025 ~ NRx Pharmaceuticals, Inc. (Nasdaq: NRXP) and its subsidiary, HOPE Therapeutics, Inc., have announced that Jonathan Javitt, MD, MPH, Founder, Chairman and Chief Executive Officer of NRx Pharmaceuticals will be presenting an update on the company at the Oppenheimer 35th Annual Healthcare Life Sciences Conference. The conference will take place virtually on February 11th-12th.
The presentation is scheduled for Wednesday, February 12th from 9:20 – 9:50 AM EST. Interested parties can access a live webcast of the presentation on NRX Events within the Investor Relations section of the Company's website. A replay of the webcast will also be available for 30 days following the event.
In addition to the presentation, management will also be available for one-on-one meetings in New York from February 10th-12th. Those interested in scheduling a meeting can contact NRx Pharmaceuticals.
NRx Pharmaceuticals is a clinical-stage biopharmaceutical company focused on developing therapeutics for central nervous system disorders such as suicidal bipolar depression, chronic pain, and PTSD. The company's lead product candidate is NRX-101, which has been designated as an FDA Breakthrough Therapy for treatment-resistant bipolar depression and chronic pain. The company plans to file an NDA for Accelerated Approval for NRX-101 in patients with bipolar depression and suicidality or akathisia. Additionally, NRX-101 has potential as a non-opioid treatment for chronic pain and complicated UTI.
More on Nyenta.com
Recently, NRx has initiated a New Drug Application filing for another product candidate, NRX-100 (IV ketamine), which has shown promising results in treating suicidal depression. This filing is based on well-controlled clinical trials conducted under the US National Institutes of Health and newly obtained data from French health authorities under a data sharing agreement. The US FDA has granted Fast Track Designation for the development of ketamine (NRX-100) as part of a protocol to treat patients with acute suicidality.
HOPE Therapeutics, Inc., a wholly-owned subsidiary of NRx Pharmaceuticals, is a development stage healthcare delivery company. Its goal is to establish a network of interventional psychiatry clinics that offer ketamine transcranial magnetics stimulation (TMS) and other life-saving therapies to patients with suicidal depression and related disorders. The company also plans to develop a digital therapeutic-enabled platform to enhance and maintain the clinical benefits of NMDA-targeted drug therapy.
This announcement serves as notice regarding NRx Pharmaceuticals' participation in the Oppenheimer 35th Annual Healthcare Life Sciences Conference and its ongoing efforts in developing innovative treatments for central nervous system disorders. Interested parties are encouraged to attend the presentation or schedule a meeting with management for further information.
The presentation is scheduled for Wednesday, February 12th from 9:20 – 9:50 AM EST. Interested parties can access a live webcast of the presentation on NRX Events within the Investor Relations section of the Company's website. A replay of the webcast will also be available for 30 days following the event.
In addition to the presentation, management will also be available for one-on-one meetings in New York from February 10th-12th. Those interested in scheduling a meeting can contact NRx Pharmaceuticals.
NRx Pharmaceuticals is a clinical-stage biopharmaceutical company focused on developing therapeutics for central nervous system disorders such as suicidal bipolar depression, chronic pain, and PTSD. The company's lead product candidate is NRX-101, which has been designated as an FDA Breakthrough Therapy for treatment-resistant bipolar depression and chronic pain. The company plans to file an NDA for Accelerated Approval for NRX-101 in patients with bipolar depression and suicidality or akathisia. Additionally, NRX-101 has potential as a non-opioid treatment for chronic pain and complicated UTI.
More on Nyenta.com
- Yonkers Mayor Spano Appoints Hope Hollinsworth-Coaxum Director of the Office of Constituent Services
- Elevate Local Launches to Help Tennessee Small Businesses Grow Online with Expert SEO and Digital Marketing
- BookCAMP 2025: The Trade Show for Independent Authors and Publishers
- Creep by Radiohead Guitar Chord Tutorial Now Available
- Olga Torres Once Again Recognized as a Top Advisor by Foreign Investment Watch
Recently, NRx has initiated a New Drug Application filing for another product candidate, NRX-100 (IV ketamine), which has shown promising results in treating suicidal depression. This filing is based on well-controlled clinical trials conducted under the US National Institutes of Health and newly obtained data from French health authorities under a data sharing agreement. The US FDA has granted Fast Track Designation for the development of ketamine (NRX-100) as part of a protocol to treat patients with acute suicidality.
HOPE Therapeutics, Inc., a wholly-owned subsidiary of NRx Pharmaceuticals, is a development stage healthcare delivery company. Its goal is to establish a network of interventional psychiatry clinics that offer ketamine transcranial magnetics stimulation (TMS) and other life-saving therapies to patients with suicidal depression and related disorders. The company also plans to develop a digital therapeutic-enabled platform to enhance and maintain the clinical benefits of NMDA-targeted drug therapy.
This announcement serves as notice regarding NRx Pharmaceuticals' participation in the Oppenheimer 35th Annual Healthcare Life Sciences Conference and its ongoing efforts in developing innovative treatments for central nervous system disorders. Interested parties are encouraged to attend the presentation or schedule a meeting with management for further information.
Filed Under: Business
0 Comments
Latest on Nyenta.com
- EQT Announces Extension of Expiration Date for Exchange Offers and Consent Solicitations and Waiver of Consent Threshold Condition
- The Ultimate Guide to the Best Jewellery Dupes in the UK: Affordable Luxury Redefined
- Florida Supreme Court Grants Petition Alleging Judicial Misconduct,in the Ninth Judicial Circuit
- Blue Luna Responds to Rising Demand for Women's Self-Defense Tools
- Wholesaler Now Expands Operations, Creating 200+ Jobs in South Florida
- Priscilla Couture Nominated For Fgi Rising Star Award
- Mastering E-commerce Photography | Key to Online Sales Success
- Top Mentor Helps Crack the 2025 Data Science Market
- New Rochelle: Apply Now for Zoning Board of Appeals Vacancy
- New Rochelle: Applications Sought for Telecommunications and Cable Advisory Committee
- City Jail Population Surpasses 7,000, Headed in Wrong Direction for Close-Rikers Plan
- DEADLINE ALERT: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Polestar Automotive
- Choosing the Right Commercial Space for Your Business
- NaturismRE Calls for Body Acceptance Education in Schools to Tackle Youth Mental Health & Physical Inactivity
- STOCKHOLDER ALERT: The M&A Class Action Firm Encourages Shareholders of EBTC, LGTY, TGI, PLYA to Act
- AMERICANS FOR CITIZEN VOTING: NEW YORK COURT OF APPEALS: ONLY CITIZENS VOTE
- Announcing The Must-Read Crypto Playbook Of 2025!
- World Premiere of "Prelude for Caroline" by Leonardo Le San Unites Music and Art
- Faruqi & Faruqi Reminds Alarum Technologies Investors of the Pending Class Action Lawsuit with a Lead Plaintiff Deadline of April 15, 2025 - ALAR
- Nanomi Receives CMO Award for Life Science Leadership in Drug Delivery USA - English USA - English